Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial

Authors :: M.R. Garcia Campelo
K.H. Lee
M. Tiseo
Angelo Delmonte
Myung-Ju Ahn
Enriqueta Felip
Maximilian Hochmair
Frank Griesinger
R. Camidge
Sanjay Popat
J-Y. Han
Dai Woo Kim
Pingkuan Zhang
Scott N. Gettinger
J.C.-H. Yang
Raffaele Califano
Q. Ni
Alexander I. Spira
H.R. Kim
Source :: Annals of Oncology. 30:ix195-ix196
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: ALK inhibitor
Oncology
Brigatinib
Crizotinib
business.industry
medicine.drug_class
Cancer research
Medicine
In patient
Hematology
business
medicine.drug

Tools